Betulinic acid - Advanced Life Sciences

Drug Profile

Betulinic acid - Advanced Life Sciences

Alternative Names: ALS-357

Latest Information Update: 06 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Advanced Life Sciences
  • Class Antineoplastics; Triterpenes
  • Mechanism of Action Apoptosis stimulants; Caspase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Malignant melanoma

Most Recent Events

  • 06 May 2011 Suspended - Phase-I for Malignant melanoma in USA (Topical)
  • 06 May 2011 Suspended - Preclinical for Malignant melanoma in USA (PO)
  • 28 Aug 2007 ALS 357 receives orphan drug status for topical treatment of metastatic melanoma in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top